Results 161 to 170 of about 289,246 (261)

A diagnosis of eosinophilic esophagitis is associated with increased life insurance premiums. [PDF]

Dis Esophagus, 2018
Leiman DA, Kochar B, Posner S, Fan C, Patel A, Shaheen O, Keller CY, Koutlas NT, Eluri S, Dellon ES.   +9 more
europepmc   +1 more source

Influence of Psychiatric Comorbidities on Postoperative Outcomes Following Pediatric Medial Patellofemoral Ligament Reconstruction

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To compare postoperative complications, rehabilitation outcomes, and health care utilization in children undergoing primary medial patellofemoral ligament reconstruction for patellofemoral instability with and without a pre‐existing mental illness. Methods The TriNetX U.S.
Haad A. Arif, Pearce Lane, Shamar T. Elliott, Amit Momaya, Kevin A. Williams   +4 more
wiley   +1 more source

Time to End the Use of Genetic Test Results in Life Insurance Underwriting. [PDF]

J Law Med Ethics, 2018
Rothstein MA.
europepmc   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Should Australia Ban the Use of Genetic Test Results in Life Insurance? [PDF]

Front Public Health, 2017
Tiller J, Otlowski M, Lacaze P.
europepmc   +1 more source

Behavioral Incentives for Exercise and Intra‐Articular Glucocorticoids for Knee Osteoarthritis: Results From a Factorially Designed Pragmatic Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to determine the benefit of a behaviorally designed incentive program and glucocorticoid injections in reducing symptoms and promoting physical activity in patients with knee osteoarthritis (KOA). Methods This was a pragmatic, multisite, factorially designed, blinded, randomized clinical trial.
Joshua F. Baker, Katherine D. Wysham, Mercedes Quinones, Bryant R. England, Kaitian Jin, Marianna Olave, Sarah Wetzel, Rachel L. Gillcrist, Criswell Lavery, Natalie Keller, Bridget Kramer, Bibianna Ateh, Hannah Brubeck, Daniel K. White, Alexis Ogdie, Rui Xiao, Tuhina Neogi, Carla R. Scanzello   +17 more
wiley   +1 more source

Unruptured intracranial aneurysms and life insurance underwriting. [PDF]

Neurol Clin Pract, 2017
Scharf E, Pelkowski S, Sahin B.
europepmc   +1 more source

Fine Particulate Matter Constituents, Ozone, and Systemic Lupus Erythematosus: A Large General‐Population Cohort Analysis With Extended Quantile g‐Computation

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to investigate whether exposure to mixture of individual fine particulate matter (PM2.5) chemical constituents is associated with incident systemic lupus erythematosus (SLE) and if ozone modifies this association and/or is associated with SLE onset.
Naizhuo Zhao, Sasha Bernatsky, Sharon Dowell, Brittany Banbury, Jeffrey R. Curtis, Grace C. Wright, Emily E. Holladay, Amy Mudano, Cristiano S. Moura, Gail S. Kerr   +9 more
wiley   +1 more source

Non‐melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin‐6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study

Arthritis &Rheumatology, Accepted Article.
Background Non‐melanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with Janus kinase inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Method This study used data from the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR‐RA) linked
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, BSRBR‐RA Contributors Group, Kimme L Hyrich   +8 more
wiley   +1 more source

Solvency II solvency capital requirement for life insurance companies based on expected shortfall. [PDF]

Eur Actuar J, 2017
Boonen TJ.
europepmc   +1 more source